Skinhealth Systems Inc (SKIN) Stock Analysis
Verdict: WATCH (do not buy)
High debt and declining revenue growth ( -8.17%) negate the value of high gross margins; the recent 57% rally is likely a technical bounce.
Investment score: 44/100
Analysis as of
Is Skinhealth Systems Inc stock worth reviewing? The TradeMates thesis
Skinhealth Systems (SKIN) is a distressed micro-cap showing a sharp technical rebound that lacks fundamental support. High debt and negative revenue growth make it a high-risk gamble.
7-factor investment score
- Valuation: 50/100 (weight 20%)
- Financial Health: 25/100 (weight 15%)
- Technical Momentum: 75/100 (weight 15%)
- Earnings Quality: 40/100 (weight 15%)
- Insider Sentiment: 45/100 (weight 10%)
- Analyst Consensus: 35/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
Skinhealth Systems Inc opportunities and risks
What speaks for SKIN
- Resilient Gross Margins
What speaks against SKIN
- Debt Maturity and Interest Burden
Peers and competitors
- USNA
- NATR
- NAGE
- NUS
- OLVI
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| SKIN | n/a | 0.5x | 6.9x | 64.9% | -2.0% | 19.0% |
| USNA | 46.4x | 0.4x | 3.2x | 76.7% | 1.0% | 0.7% |
| NATR | 19.5x | 0.8x | 7.1x | 72.7% | 4.1% | 6.1% |
| NAGE | 15.2x | 2.2x | 10.3x | 64.3% | 14.3% | 1.4% |
| NUS | 4.7x | 0.2x | 2.6x | 69.3% | 3.8% | 16.3% |
| OLVI | n/a | 3.1x | n/a | 23.4% | -26.0% | -12.2% |
| Peer median | 15.2x | 0.8x | 3.2x | 69.3% | 3.8% | 1.4% |
Frequently asked questions about Skinhealth Systems Inc (SKIN)
Is SKIN stock a good investment?
The TradeMates model rates Skinhealth Systems Inc as WATCH (do not buy) with an investment score of 44/100. Skinhealth Systems (SKIN) is a distressed micro-cap showing a sharp technical rebound that lacks fundamental support. High debt and negative revenue growth make it a high-risk gamble. This is algorithmic model output, not personal investment advice.
Is SKIN stock a buy?
The TradeMates model verdict for SKIN is WATCH (do not buy) with an investment score of 44/100. Treat this as a model signal to review, not a personal buy recommendation.